Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328643 | 0.86 | JAK2 (0.57) | JAK2JAK1NR1D1GPR119USP30 | |
| SCHEMBL8111279 | 0.83 | JAK2 (0.78) | JAK2JAK1NR1D1GPR119USP30 | |
| SCHEMBL8111282 | 0.83 | JAK2 (0.78) | JAK2JAK1NR1D1GPR119USP30 | |
| SCHEMBL4329728 | 0.82 | JAK2 (0.51) | JAK2JAK1NR1D1GPR119USP30 | |
| SCHEMBL4318763 | 0.81 | MEN1 (0.53) | JAK2JAK1GPR119USP30MEN1 | |
| SCHEMBL4302407 | 0.81 | TP53 (0.49) | GPR119OPRK1MEN1KMT2AKDM1A | |
| SCHEMBL4304098 | 0.80 | MEN1 (0.54) | GPR119OPRK1MEN1KMT2A | |
| SCHEMBL4302417 | 0.79 | MEN1 (0.51) | GPR119OPRK1MEN1KMT2AKDM1A | |
| SCHEMBL4307829 | 0.78 | MEN1 (0.48) | GPR119OPRK1MEN1KMT2A | |
| SCHEMBL621706 | 0.78 | GPR119 (0.51) | JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | SLC6A2, TPH1, SLC6A3 | JAK2 2020/4885JAK1 1669/4885NR1D1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.